Logo image of OCGN

OCUGEN INC (OCGN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OCGN - US67577C1053 - Common Stock

1.49 USD
-0.1 (-6.29%)
Last: 1/8/2026, 8:00:02 PM
1.5284 USD
+0.04 (+2.58%)
After Hours: 1/8/2026, 8:00:02 PM
Fundamental Rating

1

OCGN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. OCGN has a bad profitability rating. Also its financial health evaluation is rather negative. OCGN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

OCGN had negative earnings in the past year.
OCGN had a negative operating cash flow in the past year.
OCGN had negative earnings in each of the past 5 years.
OCGN had a negative operating cash flow in each of the past 5 years.
OCGN Yearly Net Income VS EBIT VS OCF VS FCFOCGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

OCGN has a worse Return On Assets (-111.15%) than 77.55% of its industry peers.
OCGN has a worse Return On Equity (-1812.06%) than 80.57% of its industry peers.
Industry RankSector Rank
ROA -111.15%
ROE -1812.06%
ROIC N/A
ROA(3y)-79.4%
ROA(5y)-83.76%
ROE(3y)-144.88%
ROE(5y)-130.94%
ROIC(3y)N/A
ROIC(5y)N/A
OCGN Yearly ROA, ROE, ROICOCGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OCGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCGN Yearly Profit, Operating, Gross MarginsOCGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

1

2. Health

2.1 Basic Checks

OCGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OCGN has more shares outstanding
OCGN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, OCGN has a worse debt to assets ratio.
OCGN Yearly Shares OutstandingOCGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
OCGN Yearly Total Debt VS Total AssetsOCGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -6.95, we must say that OCGN is in the distress zone and has some risk of bankruptcy.
OCGN's Altman-Z score of -6.95 is on the low side compared to the rest of the industry. OCGN is outperformed by 65.85% of its industry peers.
A Debt/Equity ratio of 8.04 is on the high side and indicates that OCGN has dependencies on debt financing.
The Debt to Equity ratio of OCGN (8.04) is worse than 80.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 8.04
Debt/FCF N/A
Altman-Z -6.95
ROIC/WACCN/A
WACC8.67%
OCGN Yearly LT Debt VS Equity VS FCFOCGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 1.85 indicates that OCGN should not have too much problems paying its short term obligations.
The Current ratio of OCGN (1.85) is worse than 77.74% of its industry peers.
OCGN has a Quick Ratio of 1.85. This is a normal value and indicates that OCGN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of OCGN (1.85) is worse than 75.47% of its industry peers.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.85
OCGN Yearly Current Assets VS Current LiabilitesOCGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

3

3. Growth

3.1 Past

OCGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.41%.
OCGN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -48.07%.
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)-48.07%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%54.23%

3.2 Future

OCGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.45% yearly.
OCGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 209.51% yearly.
EPS Next Y-20.25%
EPS Next 2Y-13.98%
EPS Next 3Y21.92%
EPS Next 5Y45.45%
Revenue Next Year49.26%
Revenue Next 2Y-23.84%
Revenue Next 3Y230.39%
Revenue Next 5Y209.51%

3.3 Evolution

OCGN Yearly Revenue VS EstimatesOCGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
OCGN Yearly EPS VS EstimatesOCGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OCGN. In the last year negative earnings were reported.
Also next year OCGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCGN Price Earnings VS Forward Price EarningsOCGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCGN Per share dataOCGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as OCGN's earnings are expected to grow with 21.92% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.98%
EPS Next 3Y21.92%

0

5. Dividend

5.1 Amount

No dividends for OCGN!.
Industry RankSector Rank
Dividend Yield 0%

OCUGEN INC

NASDAQ:OCGN (1/8/2026, 8:00:02 PM)

After market: 1.5284 +0.04 (+2.58%)

1.49

-0.1 (-6.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)03-03 2026-03-03/amc
Inst Owners21.25%
Inst Owner Change0%
Ins Owners1.12%
Ins Owner Change0%
Market Cap465.36M
Revenue(TTM)5.37M
Net Income(TTM)-64.02M
Analysts81.82
Price Target9.18 (516.11%)
Short Float %19.18%
Short Ratio16.96
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.9%
Min EPS beat(2)-22.55%
Max EPS beat(2)14.75%
EPS beat(4)3
Avg EPS beat(4)3.39%
Min EPS beat(4)-22.55%
Max EPS beat(4)14.75%
EPS beat(8)7
Avg EPS beat(8)15.68%
EPS beat(12)9
Avg EPS beat(12)14.24%
EPS beat(16)10
Avg EPS beat(16)-204.99%
Revenue beat(2)2
Avg Revenue beat(2)248.45%
Min Revenue beat(2)212.3%
Max Revenue beat(2)284.59%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)38.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.35%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)98.46%
Revenue NY rev (1m)2.66%
Revenue NY rev (3m)54.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 86.66
P/FCF N/A
P/OCF N/A
P/B 131.72
P/tB 131.72
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.02
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -111.15%
ROE -1812.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.4%
ROA(5y)-83.76%
ROE(3y)-144.88%
ROE(5y)-130.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 8.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.82%
Cap/Sales 3.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.85
Altman-Z -6.95
F-Score1
WACC8.67%
ROIC/WACCN/A
Cap/Depr(3y)863.08%
Cap/Depr(5y)672.89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
EPS Next Y-20.25%
EPS Next 2Y-13.98%
EPS Next 3Y21.92%
EPS Next 5Y45.45%
Revenue 1Y (TTM)-48.07%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%54.23%
Revenue Next Year49.26%
Revenue Next 2Y-23.84%
Revenue Next 3Y230.39%
Revenue Next 5Y209.51%
EBIT growth 1Y3.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.12%
OCF growth 3YN/A
OCF growth 5YN/A

OCUGEN INC / OCGN FAQ

What is the fundamental rating for OCGN stock?

ChartMill assigns a fundamental rating of 1 / 10 to OCGN.


What is the valuation status for OCGN stock?

ChartMill assigns a valuation rating of 1 / 10 to OCUGEN INC (OCGN). This can be considered as Overvalued.


What is the profitability of OCGN stock?

OCUGEN INC (OCGN) has a profitability rating of 0 / 10.


What is the financial health of OCUGEN INC (OCGN) stock?

The financial health rating of OCUGEN INC (OCGN) is 1 / 10.